Targeting the insulin-like growth factor-1 receptor in MTAP-deficient renal cell carcinoma

Renal cell carcinoma (RCC) has emerged as a metabolic disease characterized by dysregulated expression of metabolic enzymes. Patients with metastatic RCC have an unusually poor prognosis and near-universal resistance to all current therapies. To improve RCC treatment and the survival rate of patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Jihao, Chang, Wen-Hsin, Fong, Lon Wolf R., Weiss, Robert H., Yu, Sung-Liang, Chen, Ching-Hsien
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6345872/
https://www.ncbi.nlm.nih.gov/pubmed/30701095
http://dx.doi.org/10.1038/s41392-019-0035-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6345872/
https://www.ncbi.nlm.nih.gov/pubmed/30701095
http://dx.doi.org/10.1038/s41392-019-0035-z

Ejemplares similares